Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation

Anti-osteoporotic activity of a blocker of the ubiquitin-proteasome system, bortezomib, has known to be achieved by directly opposed action in increased bone formation by osteoblasts and in decreased bone destruction by osteoclasts. However, the mechanisms underlying the proteasome blocker inhibitio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyunghee, Kim, Mi Yeong, Ahn, Heejin, Kim, Han-Sung, Shin, Hong-In, Jeong, Daewon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666736/
https://www.ncbi.nlm.nih.gov/pubmed/28946669
http://dx.doi.org/10.3390/ijms18102054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666736/
https://www.ncbi.nlm.nih.gov/pubmed/28946669
http://dx.doi.org/10.3390/ijms18102054

Ejemplares similares